Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia
John N. Allan, Ian W. Flinn, Tanya Siddiqi, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 14, pp. 2593-2601
Open Access | Times Cited: 21

Showing 21 citing articles:

Prognostication in chronic lymphocytic leukemia
Riccardo Moia, Gianluca Gaïdano
Seminars in Hematology (2024) Vol. 61, Iss. 2, pp. 83-90
Open Access | Times Cited: 6
Chronic Lymphocytic Leukemia: Time-Limited Therapy in the First-Line Setting and Role of Minimal Residual Disease
Janina Stumpf, Othman Al‐Sawaf
Current Oncology Reports (2024) Vol. 26, Iss. 2, pp. 136-146
Open Access | Times Cited: 5
Prognostic factors in chronic lymphocytic leukaemia – the old, the new and the future
Sean McKeague, Constantine S. Tam
Leukemia & lymphoma/Leukemia and lymphoma (2025), pp. 1-11
Closed Access
Perspectives on Current Challenges and Emerging Approaches for Lymphoma Management From the 1st Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference
Alexey V. Danilov, Craig S. Sauter, Tycel Phillips, et al.
Clinical Lymphoma Myeloma & Leukemia (2025)
Closed Access
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
Jennifer R. Brown, John F. Seymour, Wojciech Jurczak, et al.
New England Journal of Medicine (2025) Vol. 392, Iss. 8, pp. 748-762
Closed Access
The preclinical discovery and development of zanubrutinib for the treatment of chronic lymphocytic leukemia
Tina Schleicher, Melanie Cohen, Solomon A. Graf
Expert Opinion on Drug Discovery (2025)
Closed Access
Upfront fixed-duration treatment strategies for chronic lymphocytic leukemia in Arab populations: a position statement from the Gulf region
Mohamed A. Yassin, Khalil Al Farsi, Anas Hamad, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access
Management strategies for patients with chronic lymphocytic leukaemia harbouring complex karyotype
Andrea Serafin, Valeria Ruocco, Alessandro Cellini, et al.
British Journal of Haematology (2025)
Open Access
Pharmacogenetic associations of GATA4 and KCNQ1 with ibrutinib cardiovascular toxicity
K. Nugent, Liyue Huang, Jai N. Patel, et al.
Pharmacogenetics and Genomics (2025)
Closed Access
Chronic Lymphocytic Leukemia: Prognostic/Predictive Factors in the Era of Novel Drugs
Antonio Urso, Enrica Antonia Martino, Antonio Cuneo, et al.
(2024)
Open Access | Times Cited: 3
Frontline Therapy of CLL—Changing Treatment Paradigms
Catherine C. Coombs
Current Hematologic Malignancy Reports (2024) Vol. 19, Iss. 2, pp. 65-74
Closed Access | Times Cited: 3
Innovative Combinations, Cellular Therapies and Bispecific Antibodies for Chronic Lymphocytic Leukemia: A Narrative Review
Andrea Visentin, Sara Frazzetto, Livio Trentin, et al.
Cancers (2024) Vol. 16, Iss. 7, pp. 1290-1290
Open Access | Times Cited: 3
Recent Advances in the Molecular Biology of Chronic Lymphocytic Leukemia: How to Define Prognosis and Guide Treatment
Annalisa Arcari, Lucia Morello, Elena Borotti, et al.
Cancers (2024) Vol. 16, Iss. 20, pp. 3483-3483
Open Access | Times Cited: 2
SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia
Saumya Easaw, Shawyon Ezzati, Catherine C. Coombs
Clinical Lymphoma Myeloma & Leukemia (2023) Vol. 23, Iss. 10, pp. 697-704
Closed Access | Times Cited: 6
MRD-directed therapy in CLL: ready for prime time?
Joanna Rhodes, Carlos López, Jacqueline C. Barrientos
Hematology (2023) Vol. 2023, Iss. 1, pp. 413-420
Closed Access | Times Cited: 5
The prognostic significance of genomic complexity in patients with CLL
Ellinor Goergen, Othman Al‐Sawaf
Leukemia & lymphoma/Leukemia and lymphoma (2024) Vol. 65, Iss. 7, pp. 873-881
Closed Access | Times Cited: 1
Chronic Lymphocytic Leukemia: Prognostic Factors in the Era of Novel Drugs
Antonio Urso, Enrica Antonia Martino, Antonio Cuneo, et al.
Cancers (2024) Vol. 16, Iss. 15, pp. 2732-2732
Open Access | Times Cited: 1
Measurable residual disease‐driven treatment in first‐line chronic lymphocytic leukaemia
M. S. Davids, Ke Lin, Amir I. Mohamed, et al.
British Journal of Haematology (2024)
Open Access | Times Cited: 1
Special issue on chronic lymphocytic leukemia: Prognostication and therapeutic options introductory editorial
Barbara Eichhorst, Elisa ten Hacken
Seminars in Hematology (2024) Vol. 61, Iss. 2, pp. 69-72
Closed Access
A CAPTIVATEing Analysis for Higher-Risk CLL
Kerry A. Rogers
Clinical Cancer Research (2023) Vol. 29, Iss. 14, pp. 2561-2562
Open Access | Times Cited: 1
Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions
Stefano Molica, Constantine S. Tam, David Allsup, et al.
Hematological Oncology (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 1
Page 1

Scroll to top